KWAME BUABENG: Open Payments
NPI 1316387673 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$621 in 29 payments from 8 companies in 2025. Trend: 2023 $219 · 2024 $619 · 2025 $621
Food & beverage: $621
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $328 |
| Neurocrine BioSciences, Inc. | 3 | $80 |
| Janssen Pharmaceuticals, Inc | 2 | $53 |
| Alkermes, Inc. | 2 | $50 |
| ABBVIE INC. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
Products named: COBENFY, INGREZZA, INVEGA SUSTENNA, ARISTADA, VRAYLAR, UZEDY, Auvelity, CAPLYTA.
Industry payments across LA — which companies pay providers there.
